InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent for Acute Neurodegenerative Treatment
January 14, 2025

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent for Acute Neurodegenerative Treatment

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, has received a U.S. patent for methods using buntanetap to treat and prevent acute brain and nerve injuries. The patent, issued on Jan. 2, 2025 (US-2025-0000846-A1), covers buntanetap’s ability to reduce neurotoxicity and mitigate neurodegenerative processes in conditions such as stroke, ischemia, traumatic brain injury, and micro infarcts. Already patented in the EU, Japan, and globally, this approval enhances Annovis’ intellectual property portfolio. CEO Maria Maccecchini, Ph.D., emphasized buntanetap’s potential to protect and restore neuronal health, expanding its applications beyond Alzheimer’s and Parkinson’s disease.

To view the full press release, visit https://ibn.fm/HFzOm

About Annovis Bio Inc.

Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is developing innovative therapies that target multiple neurotoxic proteins, with the goal of restoring brain function and improving the quality of life for patients.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).